Phospholipid Transfer Protein (Pltp) Deficient Mice Absorb Less Cholesterol

Ruijie Liu,Jahangir Iqbal,M. Mahmood Hussain,Xian-Cheng Jiang

DOI: https://doi.org/10.1161/ATVBAHA.107.149914

2006-01-01

Abstract:These results indicate that PLTP deficiency results in reduced cholesterol uptake as well as secretion by the intestine. We suggest that PLTP could be a useful target to lower plasma cholesterol levels, thus reducing atherosclerosis.

What problem does this paper attempt to address?

Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency

Xian-Cheng Jiang,Shucun Qin,Chunping Qiao,Koichi Kawano,Min Lin,Anna Skold,Xiao Xiao,Alan R. Tall

DOI: https://doi.org/10.1038/89977

IF: 82.9

2001-01-01

Nature Medicine

Abstract:Increased secretion and levels of ApoB-containing lipoproteins (BLp) commonly occur in familial hyperlipidemia, obesity and diabetes. The plasma phospholipid-transfer protein (PLTP) is known to mediate transfer of phospholipids between BLp and HDL during their intravascular metabolism. To address a possible role of PLTP in dyslipidemia and atherogenesis, we bred mice deficient in the gene encoding PLTP (PLTP-deficient mice) using different hyperlipidemic mouse strains. In ApoB-transgenic and ApoE-deficient backgrounds, PLTP deficiency resulted in reduced production and levels of BLp and markedly decreased atherosclerosis. BLp secretion was diminished in hepatocytes from ApoB-transgenic PLTP-deficient mice, a defect that was corrected when PLTP was reintroduced in adenovirus. The studies reveal a major, unexpected role of PLTP in regulating the secretion of BLp and identify PLTP as a therapeutic target.
Targeted Mutation of Plasma Phospholipid Transfer Protein Gene Markedly Reduces High-Density Lipoprotein Levels.

XC Jiang,C Bruce,J Mar,M Lin,Y Ji,OL Francone,AR Tall

DOI: https://doi.org/10.1172/jci5578

IF: 19.456

1999-01-01

Journal of Clinical Investigation

Abstract:It has been proposed that the plasma phospholipid transfer protein (PLTP) facilitates the transfer of phospholipids and cholesterol from triglyceride-rich lipoproteins (TRL) into high-density lipoproteins (HDL). To evaluate the in vivo role of PLTP in lipoprotein metabolism, we used homologous recombination in embryonic stem cells and produced mice with no PLTP gene expression. Analysis of plasma of F2 homozygous PLTP-/- mice showed complete loss of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, sphingomyelin, and partial loss of free cholesterol transfer activities. Moreover, the in vivo transfer of [3H]phosphatidylcholine ether from very-low-density proteins (VLDL) to HDL was abolished in PLTP-/- mice. On a chow diet, PLTP-/- mice showed marked decreases in HDL phospholipid (60%), cholesterol (65%), and apo AI (85%), but no significant change in non-HDL lipid or apo B levels, compared with wild-type littermates. On a high-fat diet, HDL levels were similarly decreased, but there was also an increase in VLDL and LDL phospholipids (210%), free cholesterol (60%), and cholesteryl ester (40%) without change in apo B levels, suggesting accumulation of surface components of TRL. Vesicular lipoproteins were shown by negative-stain electron microscopy of the free cholesterol- and phospholipid-enriched IDL/LDL fraction. Thus, PLTP is the major factor facilitating transfer of VLDL phospholipid into HDL. Reduced plasma PLTP activity causes markedly decreased HDL lipid and apoprotein, demonstrating the importance of transfer of surface components of TRL in the maintenance of HDL levels. Vesicular lipoproteins accumulating in PLTP-/- mice on a high-fat diet could influence the development of atherosclerosis.
Phospholipid Transfer Protein Gene Knock-out Mice Have Low High Density Lipoprotein Levels, Due to Hypercatabolism, and Accumulate Apoa-Iv-rich Lamellar Lipoproteins.

SC Qin,K Kawano,C Bruce,M Lin,C Bisgaier,AR Tall,XC Jiang

DOI: https://doi.org/10.1016/s0022-2275(20)32061-7

IF: 6.676

2000-01-01

Journal of Lipid Research

Abstract:Phospholipid transfer protein gene knock-out (Pltp KO) mice have defective transfer of very low density lipoprotein (VLDL) phospholipids into high density lipoprotein (HDL) and markedly decreased HDL levels (Jiang et al. 1999. J. Clin. Invest. 103: 907–914). These animals also accumulated VLDL- and LDL-sized lipoproteins on a high saturated fat diet. The goals of this study were to further characterize the abnormal lipoproteins of Pltp KO mice and to determine the mechanisms responsible for low HDL levels. A lipoprotein fraction enriched in lamellar structures was isolated from the low density lipoprotein (LDL) region and was shown to be phospholipid- and free cholesterol-rich and to have apoA-IV (55%) and apoE (25%) as major apolipoproteins. The lamellar lipoproteins accumulating in these mice probably represent surface material derived from triglyceride-rich lipoproteins (TRL). The HDL was found to be protein-rich (primarily apoA-I) and specifically depleted in phosphatidylcholine (PC) (28% in wild-type mice (WT) vs. 15% in Pltp KO mice, P < 0.001). Unexpectedly, turnover studies using autologous HDL revealed a profound 4-fold increase in the catabolism of HDL protein and cholesteryl ester in Pltp KO mice compared to wild-type, with minor differences in synthesis rates. In contrast, injection of WT mouse HDL into Pltp KO mice showed only a 2-fold increase in fractional catabolism. Reminiscent of the defect in Tangier disease, the failure of transfer of PC from TRL into the HDL fraction results in dramatic hypercatabolism of HDL. These results suggest that defective phospholipid transfer from TRL into HDL, arising from decreased lipolysis or decreased PLTP activity, could lead to hypoalphalipoproteinemia characterized by hypercatabolism of HDL protein. —Qin, S., K. Kawano, C. Bruce, M. Lin, C. Bisgaier, A. R. Tall, and X-c. Jiang. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins.
Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants.

Xian-Cheng Jiang,Zhiqiang Li,Ruijie Liu,Xiao Ping Yang,Meihui Pan,Laurent Lagrost,Edward A Fisher,Kevin Jon Williams

DOI: https://doi.org/10.1074/jbc.M500007200

2005-01-01

Abstract:Genetic deficiency of the plasma phospholipid transfer protein (PLTP) in mice unexpectedly causes a substantial impairment in liver secretion of apolipoprotein-B (apoB), the major protein of atherogenic lipoproteins. To explore the mechanism, we examined the three known pathways for hepatic apoB secretory control, namely endoplasmic reticulum (ER)/proteasome-associated degradation (ERAD), post-ER pre-secretory proteolysis (PERPP), and receptor-mediated degradation, also known as re-uptake. First, we found that ERAD and cell surface re-uptake were not active in PLTP-null hepatocytes. Moreover, ER-to-Golgi blockade by brefeldin A, which enhances ERAD, equalized total apoB recovery from PLTP-null and wild-type cells, indicating that the relevant process occurs post-ER. Second, because PERPP can be stimulated by intracellular reactive oxygen species (ROS), we examined hepatic redox status. Although we found previously that PLTP-null mice exhibit elevated plasma concentrations of vitamin E, a lipid anti-oxidant, we now discovered that their livers contain significantly less vitamin E and significantly more lipid peroxides than do livers of wild-type mice. Third, to establish a causal connection, the addition of vitamin E or treatment with an inhibitor of intracellular iron-dependent peroxidation, desferrioxamine, abolished the elevation in cellular ROS as well as the defect in apoB secretion from PLTP-null hepatocytes. Overall, we conclude that PLTP deficiency decreases liver vitamin E content, increases hepatic oxidant tone, and substantially enhances ROS-dependent destruction of newly synthesized apoB via a post-ER process. These findings are likely to be broadly relevant to hepatic apoB secretory control in vivo.
Phospholipid Transfer Protein (PLTP) Deficiency Attenuates High Fat Diet Induced Obesity and Insulin Resistance.

Guohua Song,Chuanlong Zong,Mingzhu Shao,Yang Yu,Qian Liu,Hui Wang,Tingting Qiu,Peng Jiao,Zheng Guo,Phoebe Lee,Yi Luo,Xian-Cheng Jiang,Shucun Qin

DOI: https://doi.org/10.1016/j.bbalip.2019.06.012

IF: 5.228

2019-01-01

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

Abstract:Increased phospholipid transfer protein (PLTP) activity has been found to be associated with obesity, and metabolic syndrome in humans. However, whether or not PLTP has a direct effect on insulin sensitivity and obesity is largely unknown. Here we analyzed the effect by using PLTP knockout (PLTP-/-) mouse model. Although, PLTP-/- mice have normal body-weight-gain under chow diet, these mice were protected from high-fat-diet-induced obesity and insulin resistance, compared with wild type mice. In order to understand the mechanism, we evaluated insulin receptor and Akt activation and found that PLTP deficiency significantly enhanced phosphorylated insulin receptor and Akt levels in high-fat-diet fed mouse livers, adipose tissues, and muscles after insulin stimulation, while total Akt and insulin receptor levels were unchanged. Moreover, we found that the PLTP deficiency induced significantly more GLUT4 protein in the plasma membranes of adipocytes and muscle cells after insulin stimulation. Finally, we found that PLTP-deficient hepatocytes had less sphingomyelins and free cholesterols in the lipid rafts and plasma membranes than that of controls and this may provide a molecular basis for PLTP deficiency-mediated increase in insulin sensitivity. We have concluded that PLTP deficiency leads to an improvement in tissue and whole-body insulin sensitivity through modulating lipid levels in the plasma membrane, especially in the lipid rafts.
Phospholipid Transfer Protein Deficiency Decreases the Content of S1P in HDL via the Loss of its Transfer Capability

Yang Yu,Shoudong Guo,Yumei Feng,Lei Feng,Yingjie Cui,Guohua Song,Tian Luo,Ke Zhang,Yiwei Wang,Xian-Cheng Jiang,Shucun Qin

DOI: https://doi.org/10.1007/s11745-013-3850-y

2013-01-01

Lipids

Abstract:Sphingosine-1-phosphate (S1P) is an amphiphilic signaling molecule, which is enriched in functional high density lipoprotein (HDL) and shows arterial protection. The distribution of S1P is changed with increased plasma phospholipid transfer protein (PLTP) activity and impaired HDL function in patients with coronary heart diseases. Therefore, we hypothesized that PLTP might transfer S1P among cells or lipoproteins. We found that plasma S1P contents were decreased by 60.1 % in PLTP knockout mice (PLTP−/−, N = 5) compared with their wild type littermates (WT, N = 5) (151.70 ± 38.59 vs. 379.32 ± 59.90 nmol/l, P <0.01). S1P content in HDL fraction (HDL-S1P) from PLTP−/− was decreased by 64.7 % compared with WT (49.36 ± 1.49 vs. 139.76 ± 2.94 nmol/l, P <0.01). The results of the S1P transfer assay indicated that PLTP could facilitate S1P transport from erythrocytes to HDL at 37 °C in D-Hanks buffer. Plasma content of apolipoprotein M, a specific adaptor of S1P, was not changed in PLTP−/− compared with WT. Therefore, we concluded that PLTP was a key factor to maintain plasma HDL-S1P, and PLTP deficiency could decrease the S1P content in plasma lipoproteins, which involves its capability of transferring S1P from erythrocyte to HDL.
Macrophage Phospholipid Transfer Protein Contributes Significantly To Total Plasma Phospholipid Transfer Activity And Its Deficiency Leads To Diminished Atherosclerotic Lesion Development

Riikka Vikstedt,Dan Ye,Jari Metso,Reeni B. Hildebrand,Theo J. C. Van Berkel,Christian Ehnholm,Matti Jauhiainen,Miranda Van Eck

DOI: https://doi.org/10.1161/01.ATV.0000254815.49414.be

2007-01-01

Abstract:Objective-Systemic phospholipid transfer protein (PLTP) deficiency in mice is associated with a decreased susceptibility to atherosclerosis, whereas overexpression of human PLTP in mice increases atherosclerotic lesion development. PLTP is also expressed by macrophage-derived foam cells in human atherosclerotic lesions, but the exact role of macrophage PLTP in atherosclerosis is unknown.Methods and Results-To clarify the role of macrophage PLTP in atherogenesis, PLTP was selectively disrupted in hematopoietic cells, including macrophages, by transplantation of bone marrow from PLTP knockout (PLTP-/-) mice into irradiated low-density lipoprotein receptor knockout mice. Selective deficiency of macrophage PLTP (PLTP-M/-M) resulted in a 29% (P < 0.01 for difference in lesion area) reduction in aortic root lesion area as compared with mice possessing functional macrophage PLTP (384 +/- 36*10(3) mu m(2) in the PLTP-M/-M group (n = 10), as compared with 539 +/- 35*10(3) mu m(2) in the PLTP+M/+M group (n = 14)) after 9 weeks of Western-type diet feeding. The decreased lesion size in the PLTP-M/-M group coincided with significantly lower serum total cholesterol, free cholesterol, and triglyceride levels in these mice. Furthermore, plasma PLTP activity in the PLTP-M/-M group was 2-fold (P < 0.001) lower than that in the PLTP-M/-M group.Conclusion-Macrophage PLTP is a significant contributor to plasma PLTP activity and deficiency of PLTP in macrophages leads to lowered atherosclerotic lesion development in low- density lipoprotein receptor knockout mice on Western-type diet.
Liver-Specific Phospholipid Transfer Protein Deficiency Reduces High-Density Lipoprotein and Non–High-Density Lipoprotein Production in Mice

Amirfarbod Yazdanyar,Wei Quan,Weijun Jin,Xian-Cheng Jiang

DOI: https://doi.org/10.1161/atvbaha.113.301628

2013-01-01

Arteriosclerosis Thrombosis and Vascular Biology

Abstract:Objective—The liver is one of the critical organs for lipoprotein metabolism and a major source for phospholipid transfer protein (PLTP) expression. The effect of liver-specific PLTP deficiency on plasma lipoprotein production and metabolism in mice was investigated. Approach and Results—We created a liver-specific PLTP-deficient mouse model. We measured plasma high-density lipoprotein (HDL) and apolipoprotein B (apoB)–containing lipoprotein (or non-HDL) levels and their production rates. We found that hepatic ablation of PLTP leads to a significant decrease in plasma PLTP activity, HDL lipids, non-HDL lipids, apoAI, and apoB levels. In addition, nuclear magnetic resonance examination of lipoproteins showed that the deficiency decreases HDL and apoB-containing lipoprotein particle numbers, as well as very low-density lipoprotein particle size, which was confirmed by electron microscopy. Moreover, HDL particles from the deficient mice are lipid-poor ones. To unravel the mechanism, we evaluated the apoB and triglyceride production rates. We found that hepatic PLTP deficiency significantly decreases apoB and triglyceride secretion rates. To investigate the role of liver PLTP on HDL production, we set up primary hepatocyte culture studies and found that the PLTP-deficient hepatocytes produce less nascent HDL. Furthermore, we found that exogenous PLTP promotes nascent HDL production through an ATP-binding cassette A 1-mediated pathway. Conclusions—Liver-specific PLTP deficiency significantly reduces plasma HDL and apoB-containing lipoprotein levels. Reduction of production rates of both particles is one of the mechanisms.
Phospholipid Transfer Protein Deficiency Impairs Apolipoprotein-B Secretion from Hepatocytes by Stimulating a Proteolytic Pathway Through a Relative Deficiency of Vitamin E and an Increase in Intracellular Oxidants*

Xian‐Cheng Jiang,Zhiqiang Li,Ruijie Liu,Xiao Ping Yang,Meihui Pan,Laurent Lagrost,Edward A. Fisher,Kevin Jon Williams

DOI: https://doi.org/10.1074/jbc.m500007200

2005-01-01

Abstract:Genetic deficiency of the plasma phospholipid transfer protein (PLTP) in mice unexpectedly causes a substantial impairment in liver secretion of apolipoprotein-B (apoB), the major protein of atherogenic lipoproteins. To explore the mechanism, we examined the three known pathways for hepatic apoB secretory control, namely endoplasmic reticulum (ER)/proteasome-associated degradation (ERAD), post-ER pre-secretory proteolysis (PERPP), and receptor-mediated degradation, also known as re-uptake. First, we found that ERAD and cell surface re-uptake were not active in PLTP-null hepatocytes. Moreover, ER-to-Golgi blockade by brefeldin A, which enhances ERAD, equalized total apoB recovery from PLTP-null and wild-type cells, indicating that the relevant process occurs post-ER. Second, because PERPP can be stimulated by intracellular reactive oxygen species (ROS), we examined hepatic redox status. Although we found previously that PLTP-null mice exhibit elevated plasma concentrations of vitamin E, a lipid anti-oxidant, we now discovered that their livers contain significantly less vitamin E and significantly more lipid peroxides than do livers of wild-type mice. Third, to establish a causal connection, the addition of vitamin E or treatment with an inhibitor of intracellular iron-dependent peroxidation, desferrioxamine, abolished the elevation in cellular ROS as well as the defect in apoB secretion from PLTP-null hepatocytes. Overall, we conclude that PLTP deficiency decreases liver vitamin E content, increases hepatic oxidant tone, and substantially enhances ROS-dependent destruction of newly synthesized apoB via a post-ER process. These findings are likely to be broadly relevant to hepatic apoB secretory control in vivo.
Pharmacologic Inhibition of Phospholipid Transfer Protein Activity Reduces Apolipoprotein-B Secretion from Hepatocytes.

Yi Luo,Lorraine Shelly,Thomas Sand,Benjamin Reidich,George Chang,Mary MacDougall,Marie-Claire Peakman,Xian-Cheng Jiang

DOI: https://doi.org/10.1124/jpet.109.161232

2009-01-01

Abstract:Phospholipid transfer protein (PLTP) plays an important role in atherogenesis, and its function goes well beyond that of transferring phospholipids between lipoprotein particles. Previous studies showed that genetic deficiency of PLTP in mice causes a substantially impaired hepatic secretion of apolipoprotein-B (apoB), the major protein of atherogenic lipoproteins. To understand whether the impaired apoB secretion is a direct result from lack of PLTP activity, in this study, we further investigated the function of PLTP in apoB secretion by using PLTP inhibitors. We identified a series of compounds containing a 3-benzazepine core structure that inhibit PLTP activity. Compound A, the most potent inhibitor, was characterized further and had little cross-reactivity with microsomal triglyceride transfer protein. Compound A reduced apoB secretion in human hepatoma cell lines and mouse primary hepatocytes. Furthermore, we confirmed that the reduction of apoB secretion mediated by compound A is PLTP-dependent, because the PLTP inhibitor had no effect on apoB secretion from PLTP-deficient hepatocytes. These studies provided evidence that PLTP activity regulates apoB secretion and pharmacologic inhibition of PLTP may be a new therapy for dyslipidemia by reducing apoB secretion.
PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity

Daoguang Yan,Mohamad Navab,Can Bruce,Alan M Fogelman,Xian-Cheng Jiang

DOI: https://doi.org/10.1194/jlr.M400053-JLR200

IF: 6.676

2004-01-01

Journal of Lipid Research

Abstract:We reported that phospholipid transfer protein (PLTP) deficiency decreased atherosclerosis in mouse models. Because the decreased atherosclerosis was accompanied by a significant decrease in plasma HDL levels, we examined the properties of PLTP knockout (PLTP0) HDL and tested its ability to prevent LDL-induced monocyte chemotactic activity in human artery wall cell cocultures. We isolated HDL and LDL from LDL receptor knockout/PLTP knockout (LDLr0/PLTP0) mice and from apolipoprotein B transgenic (apoBTg)/PLTP0 mice as well as their controls. PLTP0 HDL was relatively rich in protein and depleted in phosphatidylcholine. Turnover studies revealed a 3.5- to 4.0-fold increase in the turnover of protein and cholesteryl ester in HDL from PLTP0 mice compared with control mice. The ability of HDL from LDLr0/PLTP0 and apoBTg/ PLTP0 mice to prevent the induction of monocyte chemotactic activity in human artery wall cell cocultures exposed to human LDL was dramatically better than that in controls. Moreover, LDL from PLTP0 mice was markedly resistant to oxidation and induced significantly less monocyte chemotactic activity compared with that in controls. In vitro, PLTP0 HDL removed significantly more oxidized phospholipids from LDL than did control HDL. jlr We conclude that PLTP deficiency improves the anti-inflammatory properties of HDL in mice and reduces the ability of LDL to induce monocyte chemotactic activity. -Yan, D., M. Navab, C. Bruce, A. M. Fogelman, and X-C. Jiang. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity.
Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion

Ruijie Liu,Mohammad R. Hojjati,Cecilia M. Devlin,Inge H. Hansen,Xian-Cheng Jiang

DOI: https://doi.org/10.1161/01.atv.0000249721.96666.e5

2007-01-01

Abstract:Objective— PLTP and apoE play important roles in lipoprotein metabolism and atherosclerosis. It is known that formation of macrophage-derived foam cells (which highly express PLTP and apoE) is the critical step in the process of atherosclerosis. We investigated the relationship between PLTP and apoE in macrophages and the atherogenic relevance in a mouse model. Methods and Results— We transplanted PLTP-deficient mouse bone marrow into apoE-deficient mice (PLTP −/− →apoE −/− ), creating a mouse model with PLTP deficiency and apoE expression exclusively in the macrophages. We found that PLTP −/− →apoE −/− mice have significantly lower PLTP activity, compared with controls (WT→apoE −/− ; 20%, P <0.01). On a Western diet, PLTP −/− →apoE −/− mice have significantly lower plasma apoE than that of WT→apoE −/− mice (63%, P <0.001), and PLTP-deficient macrophages secrete significantly less apoE than WT macrophages (44%, P <0.01). Moreover, PLTP −/− →apoE −/− mice have significantly higher plasma cholesterol (98%, P <0.001) and phospholipid (107%, P <0.001) than that of WT→apoE −/− mice, thus increasing atherosclerotic lesions in the aortic arch and root (403%, P <0.001), as well as the entire aorta (298%, P <0.001). Conclusions— Macrophage PLTP deficiency causes a significant reduction of apoE secretion from the cells, and this in turn promotes the accumulation of cholesterol in the circulation and accelerates the development of atherosclerosis.
Phospholipid transfer protein deficiency in mice impairs macrophage reverse cholesterol transport in vivo.

Yanhong Si,Ying Zhang,Xiaofeng Chen,Lei Zhai,Guanghai Zhou,Ailing Yu,Haijun Cao,Qin Shucun

DOI: https://doi.org/10.1177/1535370216641218

2016-01-01

Experimental Biology and Medicine

Abstract:Phospholipid transfer protein is expressed in various cell types and secreted into plasma, where it transfers phospholipids between lipoproteins and modulates the composition of high-density lipoprotein particles. Phospholipid transfer protein deficiency in vivo can lower high-density lipoprotein cholesterol level significantly and impact the biological quality of high-density lipoprotein. Considering high-density lipoprotein was a critical determinant for reverse cholesterol transport, we investigated the role of systemic phospholipid transfer protein deficiency in macrophage reverse cholesterol transport in vivo After the littermate phospholipid transfer protein KO and WT mice were fed high-fat diet for one month, they were injected intraperitoneally with (3)H-cholesterol-labeled and acLDL-loaded macrophages. Then the appearance of (3)H-tracer in plasma, liver, bile, intestinal wall, and feces over 48 h was determined. Plasma lipid analysis indicated phospholipid transfer protein deficiency lowered total cholesterol, high-density lipoprotein-C and apolipoprotein A1 levels significantly but increased triglyceride level in mice. The isotope tracing experiment showed (3)H-cholesterol of plasma was decreased by 68% for male and 62% for female, and (3)H-tracer of bile was decreased by 37% for male and 21% for female in phospholipid transfer protein KO mice compared with WT mice. However, there was no difference in liver, and (3)H-tracer of intestinal wall was increased by 43% for male and 27% for female. Finally, (3)H-tracer of fecal excretion in phospholipid transfer protein KO mice was reduced significantly by 36% for male and 43% for female during 0-24 h period, but there was no significant difference during 24-48 h period. Meanwhile, Western Blot analysis showed the expressions of reverse cholesterol transport -related protein liver X receptor α (LXRα), ATP binding cassette transporter A1, and cholesterol 7α-hydroxylase A1 were upregulated in liver of phospholipid transfer protein KO mice compared with WT mice. These data reveal that systemic phospholipid transfer protein deficiency in mice impairs macrophage-specific reverse cholesterol transport in vivo.
Effect of phospholipid transfer protein on plasma sphingosine-1-phosphate

Quiana Jones,Jiao Zheng,Zhiqiang Li,Mulin He,Xiang Li,Kezhi Dai,Tilla S Worgall,Yang Yu,Xian-Cheng Jiang

DOI: https://doi.org/10.1016/j.jbc.2024.107837

Abstract:Plasma phospholipid transfer protein (PLTP) is a risk factor for cardiovascular diseases. Sphingosine-1-phosphate (S1P), carried by high-density lipoprotein (HDL), is a potent lipid mediator and is also associated with cardiovascular diseases. We found that germline Pltp gene knockout (KO) mice have decreased circulating S1P without influencing apoM, a major S1P carrier on HDL. We then hypothesized that, like apoM, PLTP is another S1P carrier. We established inducible Pltp-KO, Apom-KO, and Pltp/Apom double KO mice and measured plasma lipoprotein and S1P levels under different diets. We found that PLTP deficiency, and the double deficiency have a similar effect on HDL reduction. Importantly, we found that all mice have about 50% reduction in plasma S1P levels, compared to WT mice, and PLTP deficiency significantly reduces apoM levels (about 40%), while apoM deficiency has no effect on PLTP activity, indicating that PLTP depletion reduces S1P through HDL reduction. To further evaluate this HDL reduction-mediated effect, we overexpressed PLTP which also caused a reduction of HDL. We found that the overexpression reduces S1P and apoM as well as apoA-I, a major apolipoprotein on HDL. Furthermore, we found that albumin (another reported S1P carrier) deficiency in mice has no effect on plasma S1P. We also found that the influence of PLTP on HDL may not require its direct binding to the particle. In conclusion, PLTP is not a direct S1P carrier. PLTP depletion or overexpression in adulthood dramatically reduces plasma S1P through HDL reduction. ApoM, but not albumin, deficiency reduces plasma S1P levels.
The Effect of Phospholipid Transfer Protein on Lipoprotein Metabolism and Atherosclerosis

QIN Shu-Cun,YU Yang

DOI: https://doi.org/10.2741/jiang1

2002-01-01

Frontiers in Bioscience

Abstract:Phospholipid transfer protein (PLTP) is a member of the lipid transfer/lipopolysaccharide binding protein gene family. Recently, the crystal structure of one of the members of the gene family, bactericidal permeability increasing protein, was solved, providing potential insights into the mechanisms of action of PLTP. These molecules contain intrinsic lipid binding sites and appear to act as carrier proteins that shuttle between lipoproteins to redistribute lipids. The phenotype of PLTP transgenic and gene knock out mice indicates that PLTP plays a major role in the metabolism of high-density lipoprotein (HDL) and apoB-containing lipoproteins and thereby influences the concentration, apolipoprotein content, and size of lipoprotein particles in plasma. Recent data indicate that PLTP deficiency in mice is associated with a decrease of atherosclerosis, despite decreased HDL levels. At lease two underlined mechanisms are involved in the reduction of atherosclerosis in PLTP deficient status, 1) reduction of apoB-containing lipoprotein production and levels; and 2) increase of anti-oxidation potential. Human studies indicated that PLTP activity positively correlated with aging, obesity, diabetes and coronary artery disease. A challenge for the future will be the inhibition of PLTP for therapeutic benefit.
Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice.

Amirfarbod Yazdanyar,Xian-Cheng Jiang

DOI: https://doi.org/10.1002/hep.25648

2012-01-01

Abstract:UNLABELLED:It is known that plasma phospholipid transfer protein (PLTP) activity influences lipoprotein metabolism. The liver is one of the major sites of lipoprotein production and degradation, as well as of PLTP expression. To address the impact of liver-expressed PLTP on lipoprotein metabolism, we created a mouse model that expresses PLTP in the liver acutely and specifically, with a PLTP-null background. This approach in mouse model preparations can also be used universally for evaluating the function of many other genes in the liver. We found that liver PLTP expression dramatically increases plasma levels of non-high-density lipoprotein (HDL) cholesterol (2.7-fold, P < 0.0001), non-HDL phospholipid (2.5-fold, P < 0.001), and triglyceride (51%, P < 0.01), but has no significant influence on plasma HDL lipids compared with controls. Plasma apolipoprotein (apo)B levels were also significantly increased in PLTP-expressing mice (2.2-fold, P < 0.001), but those of apoA-I were not. To explore the mechanism involved, we examined the lipidation and secretion of nascent very low-density lipoprotein (VLDL), finding that liver PLTP expression significantly increases VLDL lipidation in hepatocyte microsomal lumina, and also VLDL secretion into the plasma. CONCLUSION:It is possible to prepare a mouse model that expresses the gene of interest only in the liver, but not in other tissues. Our results suggest, for the first time, that the major function of liver PLTP is to drive VLDL production and makes a small contribution to plasma PLTP activity.
Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice.

Axel Schlitt,Jin Liu,Daoguang Yan,Mary Mondragon-Escorpizo,Allen J Norin,Xian-Cheng Jiang

DOI: https://doi.org/10.1016/j.bbalip.2004.12.011

IF: 5.228

2005-01-01

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

Abstract:We previously reported that phospholipid transfer protein-deficient (PLTP KO) mice exhibit a lower rate of atherosclerosis. We proposed two possible mechanisms: a reduction in hepatic apoB secretion (Nat Med 7 (2001) 847) and induction of lipoprotein anti-oxidation activity (J Biol Chem 277 (2002) 31850). We now hypothesized that PLTP KO mice may exhibit an anti-inflammatory state per se. First, we found that PLTP KO mice have significantly lower IL-6 levels than wild type (WT) mice. Secondly, we found that IL-6 treatment increased plasma TNFα levels in WT mice, but not in PLTP KO mice. Thirdly, we used flow cytometric analyses to measure the mean fluorescence intensity of I-Ab, a MHC-class II molecule, on peripheral monocytes and found that IL-6 treatment significantly increased the I-Ab-positive cell levels in WT mice, whereas no changes were observed in the cell levels in PLTP KO mice. The results of our experiments demonstrated an anti-inflammatory effect of PLTP deficiency as a further aspect of its proatherogenic potency.
Phospholipid Transfer Protein Is Regulated by Liver X Receptors in Vivo

Guoqing Cao,Thomas P Beyer,Xiao Ping Yang,Robert J Schmidt,Youyan Zhang,William R Bensch,Raymond F Kauffman,Hong Gao,Timothy P Ryan,Yu Liang,Patrick I Eacho,Xian-Cheng Jiang

DOI: https://doi.org/10.1074/jbc.M207187200

IF: 5.485

2002-01-01

Journal of Biological Chemistry

Abstract:Liver X receptors (LXR) belong to the nuclear receptor superfamily that can regulate important lipid metabolic pathways. The plasma phospholipid transfer protein (PLTP) is known to mediate transfer of phospholipids from triglyceride-rich lipoproteins to high density lipoprotein (HDL) and plays a critical role in HDL metabolism. We report here that a specific LXR agonist, T0901317, elevated HDL cholesterol and phospholipid in C57/BL6 mice and generated enlarged HDL particles that were enriched in cholesterol, ApoAI, ApoE, and phospholipid. The appearance of these HDL particles upon oral dosing of T0901317 in C57/BL6 mice was closely correlated with the increased plasma PLTP activity and liver PLTP mRNA levels. Nuclear run-on assay indicated that the effect of LXR agonist on PLTP expression was at the transcriptional level. In mouse peritoneal macrophage cells, PLTP expression was also up-regulated by the LXR/RXR (retinoid X receptor) heterodimer. However, cholesterol efflux in mouse peritoneal macrophage cells from PLTP-deficient mice (PLTP0) was not significantly different from wild type animals. Although in PLTP-deficient mice, the induction of HDL cholesterol as well as HDL particle size increase persisted, the extent of the induction was greatly attenuated. We conclude that PLTP is a direct target gene of LXRs in vivo and plays an important role in LXR agonist-mediated HDL cholesterol and size increase in mice.
Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis

Ke Zhang,Jiao Zheng,Yunqin Chen,Jibin Dong,Zhiqiang Li,Yeun-Po Chiang,Mulin He,Qingxia Huang,Huiru Tang,Xian-Cheng Jiang

DOI: https://doi.org/10.1016/j.atherosclerosis.2021.03.011

IF: 5.3

2021-05-01

Atherosclerosis

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background and aims</h3><p>Atherosclerosis progression and regression studies are related to its prevention and treatment. Although we have gained extensive knowledge on germline phospholipid transfer protein (PLTP) deficiency, the effect of inducible PLTP deficiency in atherosclerosis remains unexplored.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We generated inducible PLTP (iPLTP)-knockout (KO) mice and measured their plasma lipid levels after feeding normal chow or Western-type diets. Adenovirus associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9) was used to induce hypercholesterolemia in the mice. Collars were placed around the common carotid arteries, and atherosclerosis progression and regression in the carotid arteries and aortic roots were evaluated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>On a normal chow diet, iPLTP-KO mice exhibited decreased cholesterol, phospholipid, apoA-I, and apoB levels compared with control mice. Furthermore, the overall amount of high-density lipoprotein (HDL) particles was reduced in these mice, but this effect was more profound for larger HDL particles. On a Western-type diet, iPLTP-KO mice again exhibited reduced levels of all tested lipids, even though the basal lipid levels were increased. Additionally, these mice displayed significantly reduced atherosclerotic plaque sizes with increased plaque stability. Importantly, inducible PLTP deficiency significantly ameliorated atherosclerosis by reducing the size of established plaques and the number of macrophages in the carotid arteries, aortic root, and whole aorta without causing lipid accumulation in the liver.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Induced PLTP deficiency in adult mice reduces plasma total cholesterol and triglycerides, prevents atherosclerosis progression, and promotes atherosclerosis regression. Thus, PLTP inhibition is a promising therapeutic approach for atherosclerosis.</p>

cardiac & cardiovascular systems,peripheral vascular disease
Abstract 19705: PLTP Deficiency Attenuates High Fat Diet Induced Obesity and Insulin Resistance

Guohua Song,Cai Zong,Mingzhu Shao,Yang Yu,Shoudong Guo,Qian Liu,Xinnong Wang,Phoebe Lee,Yi Luo,Zheng Guo,Xian‐Cheng Jiang,Shucun Qin

IF: 37.8

2017-01-01

Circulation

Abstract:Introduction: Increased phospholipid transfer protein (PLTP) activity has been found to be associated with obesity, and metabolic syndrome in humans. Hypothesis: PLTP might have a direct effect on insulin sensitivity and obesity. Methods: Here we analyzed the effect by using PLTP knockout (PLTP-/-) mouse model. Results: Although, PLTP-/- mice have normal body-weight-gain under chow diet, these mice were protected from high-fat-diet-induced obesity and insulin resistance, compared with wild type mice. In order to understand the mechanism, we evaluated insulin receptor and Akt activation and found that PLTP deficiency significantly enhanced phosphorylated insulin receptor and Akt levels in high-fat-diet fed mouse livers, adipose tissues, and muscles after insulin stimulation, while total Akt and insulin receptor levels were unchanged. Moreover, we found that the deficiency induced significantly more GLUT4 immunostaining in the plasma membranes of adipocytes and muscle cells after insulin stimulation. Finall...

Phospholipid Transfer Protein (Pltp) Deficient Mice Absorb Less Cholesterol

Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency

Targeted Mutation of Plasma Phospholipid Transfer Protein Gene Markedly Reduces High-Density Lipoprotein Levels.

Phospholipid Transfer Protein Gene Knock-out Mice Have Low High Density Lipoprotein Levels, Due to Hypercatabolism, and Accumulate Apoa-Iv-rich Lamellar Lipoproteins.

Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants.

Phospholipid Transfer Protein (PLTP) Deficiency Attenuates High Fat Diet Induced Obesity and Insulin Resistance.

Phospholipid Transfer Protein Deficiency Decreases the Content of S1P in HDL via the Loss of its Transfer Capability

Macrophage Phospholipid Transfer Protein Contributes Significantly To Total Plasma Phospholipid Transfer Activity And Its Deficiency Leads To Diminished Atherosclerotic Lesion Development

Liver-Specific Phospholipid Transfer Protein Deficiency Reduces High-Density Lipoprotein and Non–High-Density Lipoprotein Production in Mice

Phospholipid Transfer Protein Deficiency Impairs Apolipoprotein-B Secretion from Hepatocytes by Stimulating a Proteolytic Pathway Through a Relative Deficiency of Vitamin E and an Increase in Intracellular Oxidants*

Pharmacologic Inhibition of Phospholipid Transfer Protein Activity Reduces Apolipoprotein-B Secretion from Hepatocytes.

PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity

Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion

Phospholipid transfer protein deficiency in mice impairs macrophage reverse cholesterol transport in vivo.

Effect of phospholipid transfer protein on plasma sphingosine-1-phosphate

The Effect of Phospholipid Transfer Protein on Lipoprotein Metabolism and Atherosclerosis

Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice.

Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice.

Phospholipid Transfer Protein Is Regulated by Liver X Receptors in Vivo

Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis

Abstract 19705: PLTP Deficiency Attenuates High Fat Diet Induced Obesity and Insulin Resistance